The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
Study Name on ClinicalTrials.gov (link is external) | A Phase 3 Study of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor |
---|---|
Study Drug | VX-661/ ivacaftor |
Type of Study Drug | CFTR Modulation |
Study Title | A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Allele With a Gating Defect That Is Clinically Demonstrated to be Ivacaftor Responsive |
Study Phase | 3 |
Study Sponsor | Vertex |
https://clinicaltrials.gov/ct2/show/NCT02412111 (link is external) | |
Participating ECFS-CTN sites | Belgium : Leuven Italy: Milan, Rome UK: Belfast, Birmingham, Leeds, London |
Age | 12 Years and Older |